3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
10
Unknown
7
Withdrawn
4
Recruiting
4
Terminated
3
Not yet recruiting
3
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Urologic Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Intraductal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Hemorrhage
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Merkel Cell
1
Breast Neoplasms
1
Advanced Ovarian Cancer
1
Adenocarcinoma Of Esophagus
1
Interventions
Paclitaxel
62
Letrozole
55
Fulvestrant
55
Trastuzumab
50
palbociclib
41
pembrolizumab
37
Cyclophosphamide
37
Carboplatin
37
Anastrozole
37
pertuzumab
35
exemestane
25
Tamoxifen
24
Capecitabine
24
ribociclib
23
abemaciclib
23
Radiotherapy
21
Docetaxel
21
olaparib
20
Doxorubicin
20
Magnetic Resonance Spectroscopy
19
trastuzumab deruxtecan
17
Surveys and Questionnaires
17
durvalumab
16
Epirubicin
16
Specimen Handling
14
Exercise
14
130-nm albumin-bound paclitaxel
14
Taxes
13
Alpelisib
13
Goserelin
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Breast Neoplasms
×
Saline Solution
×
Clear all
NCT04895358
2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
340 enrolled